Associations - EGFR L858R + EGFR T790M

EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib + afatinib Sensitive: B - Late Trials	osimertinib + afatinib Sensitive: B - Late Trials
EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer NSCLC	erlotinib Resistant: C3 – Early Trials	erlotinib Resistant: C3 – Early Trials
EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: C3 – Early Trials	osimertinib Sensitive: C3 – Early Trials
EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: C3 – Early Trials	afatinib Sensitive: C3 – Early Trials
EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer NSCLC	gefitinib Resistant: C3 – Early Trials	gefitinib Resistant: C3 – Early Trials
EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	gefitinib Resistant: C4 – Case Studies	gefitinib Resistant: C4 – Case Studies
EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Lung Adenocarcinoma LUAD	EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Lung Adenocarcinoma LUAD	gefitinib Resistant: D – Preclinical	gefitinib Resistant: D – Preclinical
EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer NSCLC	CH7233163 Sensitive: D – Preclinical	CH7233163 Sensitive: D – Preclinical
EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer NSCLC	rociletinib Sensitive: D – Preclinical	rociletinib Sensitive: D – Preclinical
EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib + BX795 Sensitive: D – Preclinical	osimertinib + BX795 Sensitive: D – Preclinical
EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer NSCLC	H002 Sensitive: D – Preclinical	H002 Sensitive: D – Preclinical
EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Lung Cancer Lung Cancer	EGFR L858R + EGFR T790M EGFR L858R + EGFR T790M	Lung Cancer Lung Cancer	osimertinib + tipifarnib Sensitive: D – Preclinical	osimertinib + tipifarnib Sensitive: D – Preclinical